{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T10:42:57Z","timestamp":1793356977076,"version":"4.5.0"},"reference-count":48,"publisher":"American Medical Association (AMA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Intern Med"],"published-print":{"date-parts":[[2026,3,1]]},"abstract":"\n Importance<\/jats:title>\n Gout is associated with increased cardiovascular risk. Whether achieving a target serum urate level lower than 6 mg\/dL with urate-lowering treatment (ULT) would reduce cardiovascular risk in patients with gout is unknown.<\/jats:p>\n <\/jats:sec>\n \n Objectives<\/jats:title>\n To evaluate the association between achieving a serum urate treatment target lower than 6 mg\/dL and cardiovascular events among patients with gout who were newly prescribed ULT.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This new-user cohort study using emulated target trial framework with up to 5-year follow-up was performed using primary care data from the Clinical Practice Research Datalink Aurum linked to hospitalization and mortality records from January 1, 2007, to March 29, 2021. Patients were 18 years or older, diagnosed with gout, had a pretreatment serum urate level higher than 6 mg\/dL, and were newly prescribed ULT. Data were analyzed from May 2024 to January 2025.<\/jats:p>\n <\/jats:sec>\n \n Exposure<\/jats:title>\n Patients were assigned to the treat-to-target (T2T) ULT arm or the non\u2013T2T ULT arm if they achieved or did not achieve a serum urate level lower than 6 mg\/dL, respectively, within 12 months of their first ULT prescription.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary outcome was first major adverse cardiovascular event within 5 years of first ULT prescription. Gout flare was the positive control outcome. Acute bronchitis, cataract, and appendicitis were included as negative control outcomes. Weighted absolute 5-year event-free survival and weighted hazard ratios (HRs) with 95% CIs were estimated.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Of 109\u202f504 patients included, the mean (SD) age was 62.9 (15.2) years, 22.2% were female, the mean (SD) disease duration was 2.5 (3.6) years, and 27.3% were included in the T2T ULT arm. Patients in the T2T ULT arm had a higher 5-year survival (weighted survival difference, 1.0%; 95% CI, 0.5%-1.6%) and lower risk of major adverse cardiovascular events (weighted HR, 0.91; 95% CI, 0.89-0.92) than those in the non\u2013T2T ULT arm. There was a greater association for people at high and very high cardiovascular risk than those with moderate risk. Patients who achieved a lower serum urate target of less than 5 mg\/dL had a larger risk reduction (weighted survival difference, 2.6%; 95% CI, 0.9%-3.6%; weighted HR, 0.77; 95% CI, 0.72-0.81). Patients in the T2T ULT arm had fewer gout flares. No differences were observed for negative control outcomes.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this cohort study among patients with gout who were newly prescribed ULT, achieving serum urate levels lower than 6 mg\/dL within 12 months was associated with a lower 5-year risk of major adverse cardiovascular events.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamainternmed.2025.7453","type":"journal-article","created":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T16:00:25Z","timestamp":1769443225000},"page":"332","source":"Crossref","is-referenced-by-count":22,"title":["Treat-to-Target Urate-Lowering Treatment and Cardiovascular Outcomes in Patients With Gout"],"prefix":"10.1001","volume":"186","author":[{"given":"Edoardo","family":"Cipolletta","sequence":"first","affiliation":[{"name":"Academic Rheumatology, University of Nottingham, Nottingham, United Kingdom"},{"name":"Department of Clinical and Molecular Sciences, Polytechnic University of Marche, Ancona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana","family":"Zverkova Sandstr\u00f6m","sequence":"additional","affiliation":[{"name":"Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Rozza","sequence":"additional","affiliation":[{"name":"Epidemiology Unit, Italian Society for Rheumatology (SIR), Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemence","family":"Leyrat","sequence":"additional","affiliation":[{"name":"Department of Medical Statistics, London School of Hygiene and Tropical Medicine, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgina","family":"Nakafero","sequence":"additional","affiliation":[{"name":"Academic Rheumatology, University of Nottingham, Nottingham, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiota","family":"Drivelegka","sequence":"additional","affiliation":[{"name":"Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony J.","family":"Avery","sequence":"additional","affiliation":[{"name":"Centre for Academic Primary Care, School of Medicine, University of Nottingham, Nottingham, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamas A.","family":"Mamas","sequence":"additional","affiliation":[{"name":"Keele Cardiovascular Research Group, Keele University, Keele, United Kingdom"},{"name":"National Institute for Health and Care Research (NIHR) Birmingham Biomedical Research Centre, Birmingham, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laila J.","family":"Tata","sequence":"additional","affiliation":[{"name":"Lifespan and Population Health Unit, School of Medicine, University of Nottingham, Nottingham, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mats","family":"Dehlin","sequence":"additional","affiliation":[{"name":"Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek","family":"Abhishek","sequence":"additional","affiliation":[{"name":"Academic Rheumatology, University of Nottingham, Nottingham, United Kingdom"},{"name":"National Institute for Health and Care Research (NIHR) Nottingham Biomedical Research Centre, Nottingham, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"6","key":"ioi250093r1","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1002\/art.40807","article-title":"Contemporary prevalence of gout and hyperuricemia in the United States and decadal trends: the National Health and Nutrition Examination Survey, 2007-2016.","volume":"71","author":"Chen-Xu","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"ioi250093r2","doi-asserted-by":"publisher","first-page":"e156","DOI":"10.1016\/S2665-9913(23)00338-7","article-title":"Gout and incidence of 12 cardiovascular diseases: a case-control study including 152?663 individuals with gout and 709?981 matched controls.","volume":"6","author":"Ferguson","year":"2024","journal-title":"Lancet Rheumatol"},{"issue":"5","key":"ioi250093r3","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1002\/acr.25292","article-title":"Unclosing premature mortality gap among patients with gout in the US general population, independent of serum urate and atherosclerotic cardiovascular risk factors.","volume":"76","author":"McCormick","year":"2024","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"5","key":"ioi250093r4","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1001\/jama.2022.11390","article-title":"Association between gout flare and subsequent cardiovascular events among patients with gout.","volume":"328","author":"Cipolletta","year":"2022","journal-title":"JAMA"},{"issue":"6","key":"ioi250093r5","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1002\/acr2.11540","article-title":"Risk of major adverse cardiovascular event following incident hospitalization for acute gout: a Western Australian population-level linked data study.","volume":"5","author":"Lopez","year":"2023","journal-title":"ACR Open Rheumatol"},{"issue":"2","key":"ioi250093r6","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1002\/art.42986","article-title":"Short-term risk of cardiovascular events in people newly diagnosed with gout.","volume":"77","author":"Cipolletta","year":"2025","journal-title":"Arthritis Rheumatol"},{"issue":"9","key":"ioi250093r7","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1136\/annrheumdis-2016-210872","article-title":"A randomised controlled trial of the efficacy and safety of allopurinol dose escalation to achieve target serum urate in people with gout.","volume":"76","author":"Stamp","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"10156","key":"ioi250093r8","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1016\/S0140-6736(18)32158-5","article-title":"Efficacy and cost-effectiveness of nurse-led care involving education and engagement of patients and a treat-to-target urate-lowering strategy versus usual care for gout: a randomised controlled trial.","volume":"392","author":"Doherty","year":"2018","journal-title":"Lancet"},{"issue":"1","key":"ioi250093r9","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","article-title":"2016 updated EULAR evidence-based recommendations for the management of gout.","volume":"76","author":"Richette","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"ioi250093r10","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/s41584-021-00657-4","article-title":"Management of gout in chronic kidney disease: a G-CAN Consensus Statement on the research priorities.","volume":"17","author":"Stamp","year":"2021","journal-title":"Nat Rev Rheumatol"},{"key":"ioi250093r11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14740338.2024.2430304","article-title":"Cardiovascular outcomes of urate-lowering therapies in patients with gout or hyperuricemia: a network meta-analysis.","author":"Yan","year":"2024","journal-title":"Expert Opin Drug Saf"},{"issue":"9","key":"ioi250093r12","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/s41584-022-00804-5","article-title":"When underlying biology threatens the randomization principle\u2014initial gout flares of urate-lowering therapy.","volume":"18","author":"Choi","year":"2022","journal-title":"Nat Rev Rheumatol"},{"issue":"7","key":"ioi250093r13","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1002\/acr.24205","article-title":"Mortality in patients with gout treated with allopurinol: a systematic review and meta-analysis.","volume":"73","author":"Hay","year":"2021","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"9","key":"ioi250093r14","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1093\/rheumatology\/kez576","article-title":"Comparative cardiovascular risk in users versus non-users of xanthine oxidase inhibitors and febuxostat versus allopurinol users.","volume":"59","author":"Ju","year":"2020","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"ioi250093r15","doi-asserted-by":"publisher","first-page":"653.e7","DOI":"10.1016\/j.amjmed.2015.01.013","article-title":"Effects of xanthine oxidase inhibitors on cardiovascular disease in patients with gout: a cohort study.","volume":"128","author":"Kim","year":"2015","journal-title":"Am J Med"},{"issue":"4","key":"ioi250093r16","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1097\/EDE.0000000000001608","article-title":"Comparative safety of gout treatment strategies on cardiovascular outcomes using observational data: clone-censor-weight target trial emulation approach.","volume":"34","author":"Yoshida","year":"2023","journal-title":"Epidemiology"},{"issue":"6","key":"ioi250093r17","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1002\/acr.24180","article-title":"2020 American College of Rheumatology guideline for the management of gout.","volume":"72","author":"FitzGerald","year":"2020","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"16","key":"ioi250093r18","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1001\/jama.2023.4221","article-title":"Emulation of randomized clinical trials with nonrandomized database analyses: results of 32 clinical trials.","volume":"329","author":"Wang","year":"2023","journal-title":"JAMA"},{"key":"ioi250093r19","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2025-087179","article-title":"Transparent reporting of observational studies emulating a target trial: the TARGET Statement.","volume":"390","author":"Cashin","year":"2025","journal-title":"BMJ"},{"issue":"10","key":"ioi250093r20","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1136\/ard.2006.055269","article-title":"EULAR evidence based recommendations for gout: part II: management: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).","volume":"65","author":"Zhang","year":"2006","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"ioi250093r21","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1136\/annrheumdis-2013-204463","article-title":"Rising burden of gout in the UK but continuing suboptimal management: a nationwide population study.","volume":"74","author":"Kuo","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"ioi250093r22","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1136\/ard-2022-222668","article-title":"Serum urate outcomes of treat-to-target urate lowering treatment: results of a nationwide cohort study from 1997 to the COVID-19 pandemic using data from the Clinical Practice Research Datalink.","volume":"81","author":"Abhishek","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"ioi250093r23","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1186\/s12874-021-01440-5","article-title":"Major adverse cardiovascular event definitions used in observational analysis of administrative databases: a systematic review.","volume":"21","author":"Bosco","year":"2021","journal-title":"BMC Med Res Methodol"},{"issue":"2","key":"ioi250093r24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3399\/BJGPO.2020.0117","article-title":"Concordance in the recording of stroke across UK primary and secondary care datasets: a population-based cohort study.","volume":"5","author":"Morgan","year":"2021","journal-title":"BJGP Open"},{"issue":"7909","key":"ioi250093r25","doi-asserted-by":"publisher","first-page":"f2350","DOI":"10.1136\/bmj.f2350","article-title":"Completeness and diagnostic validity of recording acute myocardial infarction events in primary care, hospital care, disease registry, and national mortality records: cohort study.","volume":"346","author":"Herrett","year":"2013","journal-title":"BMJ"},{"issue":"10","key":"ioi250093r26","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1136\/emj.2010.095885","article-title":"Incidence of acute myocardial infarction resulting in sudden death outside the hospital.","volume":"28","author":"Adnet","year":"2011","journal-title":"Emerg Med J"},{"key":"ioi250093r27","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jclinepi.2016.04.014","article-title":"Specifying a target trial prevents immortal time bias and other self-inflicted injuries in observational analyses.","volume":"79","author":"Hern\u00e1n","year":"2016","journal-title":"J Clin Epidemiol"},{"issue":"3","key":"ioi250093r28","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1007\/s40471-024-00346-2","article-title":"The clone-censor-weight method in pharmacoepidemiologic research: foundations and methodological implementation.","volume":"11","author":"Gaber","year":"2024","journal-title":"Curr Epidemiol Rep"},{"issue":"1","key":"ioi250093r29","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.cmpb.2003.10.004","article-title":"Adjusted survival curves with inverse probability weights.","volume":"75","author":"Cole","year":"2004","journal-title":"Comput Methods Programs Biomed"},{"issue":"5","key":"ioi250093r30","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1093\/ije\/dyaa057","article-title":"Reflection on modern methods: trial emulation in the presence of immortal-time bias: assessing the benefit of major surgery for elderly lung cancer patients using observational data.","volume":"49","author":"Maringe","year":"2020","journal-title":"Int J Epidemiol"},{"issue":"4","key":"ioi250093r31","doi-asserted-by":"publisher","first-page":"461","DOI":"10.7326\/M21-2347","article-title":"Allopurinol initiation and all-cause mortality among patients with gout and concurrent chronic kidney disease: a population-based cohort study.","volume":"175","author":"Wei","year":"2022","journal-title":"Ann Intern Med"},{"issue":"3","key":"ioi250093r32","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1177\/0962280217735560","article-title":"Adjustment for treatment changes in epilepsy trials: a comparison of causal methods for time-to-event outcomes.","volume":"28","author":"Dodd","year":"2019","journal-title":"Stat Methods Med Res"},{"issue":"34","key":"ioi250093r33","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC Guidelines on cardiovascular disease prevention in clinical practice.","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J"},{"issue":"4","key":"ioi250093r34","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1002\/sim.4067","article-title":"Multiple imputation using chained equations: issues and guidance for practice.","volume":"30","author":"White","year":"2011","journal-title":"Stat Med"},{"issue":"1","key":"ioi250093r35","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s12963-023-00302-0","article-title":"Completeness, agreement, and representativeness of ethnicity recording in the United Kingdom\u2019s Clinical Practice Research Datalink (CPRD) and linked Hospital Episode Statistics (HES).","volume":"21","author":"Shiekh","year":"2023","journal-title":"Popul Health Metr"},{"issue":"3","key":"ioi250093r36","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2100028","article-title":"Comparative effectiveness of allopurinol and febuxostat in gout management.","volume":"1","author":"O\u2019Dell","year":"2022","journal-title":"NEJM Evid"},{"issue":"10264","key":"ioi250093r37","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1016\/S0140-6736(20)32234-0","article-title":"Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial.","volume":"396","author":"Mackenzie","year":"2020","journal-title":"Lancet"},{"issue":"13","key":"ioi250093r38","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1056\/NEJMoa1710895","article-title":"Cardiovascular safety of febuxostat or allopurinol in patients with gout.","volume":"378","author":"White","year":"2018","journal-title":"N Engl J Med"},{"issue":"11","key":"ioi250093r39","doi-asserted-by":"publisher","first-page":"5463","DOI":"10.1093\/rheumatology\/keab335","article-title":"The inflammatory role of silent urate crystal deposition in intercritical gout.","volume":"60","author":"Diaz-Torne","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"ioi250093r40","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1111\/1756-185X.13811","article-title":"The burden of subclinical intra-articular inflammation in gout.","volume":"23","author":"Chowalloor","year":"2020","journal-title":"Int J Rheum Dis"},{"issue":"8","key":"ioi250093r41","doi-asserted-by":"publisher","first-page":"e507","DOI":"10.1016\/S2665-9913(24)00117-6","article-title":"Global, regional, and national burden of gout, 1990-2020, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021.","volume":"6","author":"Cross","year":"2024","journal-title":"Lancet Rheumatol"},{"issue":"7","key":"ioi250093r42","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1136\/annrheumdis-2017-212534","article-title":"MR-PheWAS: exploring the causal effect of SUA level on multiple disease outcomes by using genetic instruments in UK Biobank.","volume":"77","author":"Li","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"10359","key":"ioi250093r43","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/S0140-6736(22)01657-9","article-title":"Allopurinol versus usual care in UK patients with ischaemic heart disease (ALL-HEART): a multicentre, prospective, randomised, open-label, blinded-endpoint trial.","volume":"400","author":"Mackenzie","year":"2022","journal-title":"Lancet"},{"issue":"3","key":"ioi250093r44","doi-asserted-by":"publisher","first-page":"e197","DOI":"10.1016\/S2665-9913(24)00248-0","article-title":"Cardiovascular events in patients with gout initiating urate-lowering therapy with or without colchicine for flare prophylaxis: a retrospective new-user cohort study using linked primary care, hospitalisation, and mortality data.","volume":"7","author":"Cipolletta","year":"2025","journal-title":"Lancet Rheumatol"},{"issue":"1","key":"ioi250093r45","doi-asserted-by":"publisher","DOI":"10.1002\/acr2.11759","article-title":"Gout flare burden in the United States: a multiyear cross-sectional survey study.","volume":"7","author":"Singh","year":"2025","journal-title":"ACR Open Rheumatol"},{"issue":"2","key":"ioi250093r46","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.ejcnurse.2010.05.001","article-title":"Nurse-led cardiovascular disease risk management intervention for patients with gout.","volume":"10","author":"McLachlan","year":"2011","journal-title":"Eur J Cardiovasc Nurs"},{"issue":"1","key":"ioi250093r47","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1001\/jamainternmed.2024.6212","article-title":"Target serum urate achievement and chronic kidney disease progression in patients with gout and kidney disease.","volume":"185","author":"Wang","year":"2025","journal-title":"JAMA Intern Med"},{"issue":"2","key":"ioi250093r48","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1046\/j.1365-2125.1997.00647.x","article-title":"Omeprazole, other antiulcer drugs and newly diagnosed gout.","volume":"44","author":"Meier","year":"1997","journal-title":"Br J Clin Pharmacol"}],"container-title":["JAMA Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/articlepdf\/2844321\/jamainternal_cipolletta_2026_oi_250093_1771882354.28063.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T16:00:38Z","timestamp":1772467238000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/fullarticle\/2844321"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,1]]},"references-count":48,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamainternmed.2025.7453","relation":{},"ISSN":["2168-6106"],"issn-type":[{"value":"2168-6106","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,1]]}}}